Kura Oncology Stock Today
| KURA Stock | USD 20.95 0.13 0.62% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Kura Oncology is trading at 20.95 as of the 23rd of September 2024, a 0.62 percent decrease since the beginning of the trading day. The stock's open price was 21.08. Kura Oncology has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Kura Oncology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of June 2024 and ending today, the 23rd of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of September 2015 | Category Healthcare | Classification Health Care |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 76.63 M outstanding shares of which 10.8 M shares are now shorted by private and institutional investors with about 18.7 trading days to cover. More on Kura Oncology
Moving against Kura Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Kura Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKura Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kura Oncology's financial leverage. It provides some insight into what part of Kura Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Kura Oncology (KURA) is traded on NASDAQ Exchange in USA. It is located in 12730 High Bluff Drive, San Diego, CA, United States, 92130 and employs 142 people. Kura Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.61 B. Kura Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 76.63 M outstanding shares of which 10.8 M shares are now shorted by private and institutional investors with about 18.7 trading days to cover.
Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73.
Check Kura Oncology Probability Of Bankruptcy
Ownership AllocationThe majority of Kura Oncology outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kura Oncology to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kura Oncology. Please pay attention to any change in the institutional holdings of Kura Oncology as this could imply that something significant has changed or is about to change at the company.
Check Kura Ownership Details
Kura Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Foresite Capital Management Iv, Llc | 2024-06-30 | 1.8 M | |
| Artal Group S A | 2024-06-30 | 1.8 M | |
| Geode Capital Management, Llc | 2024-06-30 | 1.7 M | |
| Assenagon Asset Management Sa | 2024-06-30 | 1.7 M | |
| Commodore Capital Lp | 2024-06-30 | 1.6 M | |
| Franklin Resources Inc | 2024-06-30 | 1.6 M | |
| Tcg Crossover Management, Llc | 2024-06-30 | 1.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | |
| Citadel Advisors Llc | 2024-06-30 | 1 M | |
| Suvretta Capital Management, Llc | 2024-06-30 | 7.1 M | |
| Blackrock Inc | 2024-06-30 | 7 M |
Kura Oncology Historical Income Statement
Kura Stock Against Markets
Kura Oncology Corporate Management
| Kathleen Ford | Chief Officer | Profile | |
| Mollie MD | Executive Development | Profile | |
| Francis Burrows | Senior Research | Profile | |
| Roger Bakale | Clinical CMC | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Marc MD | Advisor | Profile | |
| Stephen MD | Chief Officer | Profile |
Additional Information and Resources on Investing in Kura Stock
When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.23) | Return On Assets (0.25) | Return On Equity (0.39) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.